21 completed. 21 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Completed 21 |
| Phase 3 | 2 | Completed 2 |
Follow Nasal Polyps: new trials by email Literature Review of Nasal Polyps trials Research Report on Nasal Polyps
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps Verekitug (UPB-101), Placebo - Chronic Rhinosinusitis With Nasal Polyps | Phase 2 | Completed | Upstream Bio Inc. | 81 | 2023-12-18 | 2026-09-18 |
| A Clinical Study of TQC2731 Injection in the Treatment of Chronic Rhinosinusitis With Nasal Polyps TQC2731 injection, TQC2731 matching placebo - Chronic Sinusitis, Nasal Polyps | Phase 2 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 80 | 2023-12-08 | 2025-04-16 |
| Subcutaneously CM310/Placebo in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CROWNS-1) CM310, Placebo - Chronic Rhinosinusitis (Diagnosis), Nasal Polyps | Phase 2 | Completed | Keymed Biosciences Co.Ltd | 56 | 2021-04-06 | 2022-06-29 |
| GB001 in Adult Participants With Chronic Rhinosinusitis GB001, Placebo - Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP), Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Phase 2 | Completed | GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc. | 97 | 2019-05-16 | 2021-08-23 |
| Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban Ifetroban, Placebo - Nasal Polyps, Asthma, Aspirin-Induced | Phase 2 | Completed | Brigham and Women's Hospital | 38 | 2018-04-26 | 2023-07-14 |
| Comparison of Methylprednisolone or Methotrexate in the Maintenance Treatment of Nasal Polyposis Emthexate, Prednol, Mometasone Furoate - Nasal Polyposis | Phase 2 | Completed | Dokuz Eylul University | 41 | 2017-09-02 | 2020-08-31 |
| Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis Benralizumab, Placebo - Chronic Rhinosinusitis (Diagnosis), Nasal Polyps | Phase 2 | Completed | Johns Hopkins University | 33 | 2017-07-01 | 2021-02-11 |
| Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Rhinosinusitis With Nasal Polyposis botox injection Multiguide - Chronic Disease, Nasal Polyposis | Phase 2 | Completed | Norwegian University of Science and Technology | 11 | 2016-10-01 | 2021-11-05 |
| Anti-Inflammatory Agent in Sinusitis AZ compound, Collection of Biological Specimens, Intranasal corticosteroid - Nasal Polyps | Phase 2 | Completed | Northwestern University | 43 | 2016-06-20 | 2022-05-25 |
| Study to Evaluate Multiple Doses in Patients With Nasal Polyposis AK001 low dose, AK001 high dose, Placebo - Nasal Polyposis | Phase 2 | Completed | Allakos Inc. | 40 | 2016-04-01 | 2021-01-25 |
| Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia dexpramipexole - Chronic Sinusitis With Nasal Polyps and Eosinophilia | Phase 2 | Completed | Knopp Biosciences | 20 | 2014-08-01 | 2021-05-18 |
| An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis Placebo (for dupilumab), Dupilumab, Mometasone furoate nasal spray - Nasal Polyps | Phase 2 | Completed | Sanofi | 60 | 2013-08-01 | 2017-06-26 |
| Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps S8 Sinus Implant, Sham procedure, Mometasone furoate nasal spray - Chronic Sinusitis, Nasal Polyps | Phase 2 / Phase 3 | Completed | Intersect ENT | 100 | 2013-01-01 | 2018-07-20 |
| Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial placebo, doxycycline 100 mg - Chronic Rhinosinusitis, Nasal Polyps | Phase 2 | Completed | University Hospital, Ghent | 33 | 2011-11-22 | 2018-06-15 |
| Effects and Safety of Budesonide Inhalation Suspension Via Transnasal Nebulization in Nasal Polyps budesonide, placebo - Nasal Polyps | Phase 2 / Phase 3 | Completed | Beijing Tongren Hospital | 57 | 2010-09-01 | 2014-10-10 |
| Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis Xolair placebo, Xolair (omalizumab) - Chronic Rhinosinusitis, Nasal Polyps | Phase 2 | Completed | Massachusetts General Hospital | 27 | 2009-12-01 | 2017-06-14 |
| Mepolizumab in Nasal Polyposis Mepolizumab, Placebo, Run In Medication - Nasal Polyps | Phase 2 | Completed | GlaxoSmithKline | 109 | 2009-05-12 | 2021-04-12 |
| Mint Tea for the Treatment of Nasal Polyps Mint tea high in rosmarinic acid, Mint tea low in rosmarinic acid - Nasal Polyps | Phase 2 | Completed | Hamilton Health Sciences Corporation | 22 | 2007-05-01 | 2011-12-09 |
| Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and Asthma Omalizumab, Placebo - Nasal Polyposis, Asthma | Phase 2 | Completed | University Hospital, Ghent | 23 | 2006-12-01 | 2011-07-13 |
| A Comparison of Beclomethasone Aqueous Spray and Aerosol Delivery Systems in Nasal Polyps Intranasal Beclomethasone aerosol, Intranasal Beclomethasone spray - Nasal Polyps | Phase 2 | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 30 | 2006-11-23 | 2017-08-28 |
Showing 20 of 21. Sign in to see all of them.
Asthma (2) · Disease (2) · Eosinophilia (2) · Rhinosinusitis (2) · Sinusitis (2) · Asthma, Aspirin-Induced (1) · Bites and Stings (1) · Chronic Disease (1) · Nose Diseases (1) · Otorhinolaryngologic Diseases (1) · Paranasal Sinus Diseases (1) · Respiratory Tract Diseases (1) · Rhinitis (1)
Pathological Conditions, Anatomical (21) · Pathological Conditions, Signs and Symptoms (21) · Polyps (21) · Nose Diseases (20) · Otorhinolaryngologic Diseases (20) · Respiratory Tract Diseases (20) · Infections (4) · Respiratory Tract Infections (4) · Bronchial Diseases (3) · Hypersensitivity (3) · Hypersensitivity, Immediate (3) · Immune System Diseases (3) · Pathologic Processes (3) · Respiratory Hypersensitivity (3) · Chemically-Induced Disorders (2)
Mometasone Furoate (4) · Omalizumab (2) · Adrenal Cortex Hormones (1) · Beclomethasone (1) · Biomarkers (1) · Botulinum Toxins, Type A (1) · Budesonide (1) · Dexpramipexole (1) · Dosage Forms (1) · Doxycycline (1) · Fluticasone (1) · Jogging (1) · MeRho-Az compound (1) · Methotrexate (1) · Methylprednisolone (1)
University Hospital, Ghent (3) · Allakos Inc. (1) · Beijing Tongren Hospital (1) · Brigham and Women's Hospital (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Dokuz Eylul University (1) · GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc. (1) · GlaxoSmithKline (1) · Hamilton Health Sciences Corporation (1) · Intersect ENT (1) · Johns Hopkins University (1) · Keymed Biosciences Co.Ltd (1) · Knopp Biosciences (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Massachusetts General Hospital (1)
United States (9) · Belgium (6) · China (3) · Germany (3) · Spain (3) · Czechia (2) · Netherlands (2) · United Kingdom (2) · Canada (1) · Norway (1) · Poland (1) · Sweden (1) · Turkey (Türkiye) (1) · Ukraine (1)
Claus Bachert, MD, PhD (2) · Anju T Peters, MD (1) · Claus Bachert (1) · Ellen J Dutta, MD (1) · Elliot Israel, MD (1) · Jody Tversky, MD (1) · Jorge A Mazza, MD (1) · Joseph K Han, MD (1) · Keith D Forwith, MD (1) · Lars Jacob Stovner, md prof (1) · Luo Zhang (1) · Luo Zhang, MD (1) · Paul K. Keith (1)
PMID 33710614, PMID 26836729, PMID 26992115, PMID 30488542, PMID 30954643, PMID 31306495, PMID 32075470, PMID 33595845, PMID 34110505, PMID 34437720, PMID 34633904, PMID 34848949, PMID 35524339, PMID 37483544, PMID 39393433
2008 (1), 2015 (1), 2019 (1), 2023 (1)